Cancer drugs help AstraZeneca beat forecasts
AstraZeneca beat expectations on sales and earnings in the first quarter of 2023, as rising revenue from cancer drugs helped compensate for a $1.5bn drop in sales of Covid-19 medicines.
The Anglo-Swedish drugmaker reported total revenue of $10.9bn, down 4 per cent year on year but it beat consensus forecasts of $10.6bn. Sales of oncology treatments rose 19 per cent year on year at constant exchange rates.
This story originally appeared on: Financial Times - Author:Hannah Kuchler
